Objective: This study aimed to assess the effectiveness of two concentrations of bupivacaine (0.25% and 0.5%) in greater occipital nerve (GON) blocks in patients with chronic migraine.Method: In this retrospective analysis, 72 patients with chronic migraine, treated between 2019 and 2021, were divided into two groups: Group 1 (0.25% bupivacaine) and Group 2 (0.5% bupivacaine). Patients received weekly GON blocks for four weeks, followed by monthly sessions for six months. Pain levels were measured using the Visual Analogue Scale (VAS) at the initial visit (VAS-1), after the first month (VAS-2), and at six months (VAS-3).Results: Both bupivacaine concentrations significantly reduced VAS scores over time. In Group 1, the mean VAS score decreased from 8.49 at baseline to 4.80 at the first month and 4.21 at six months. In Group 2, the VAS scores decreased from 8.65 to 4.35 at the first month and 3.2 at six months. The reductions within each group were statistically significant (p
Seren et al. (Tue,) studied this question.